S124 Derivation and validation of the bronchiectasis severity index: an international multicentre observational study. (14th November 2013)

• Record Type: Journal Article
• Authors: Chalmers, JD; Goeminne, P; Aliberti, S; McDonnell, M; Lonzi, S; Davidson, J; Poppelwell, L; Salih, W; Pesci, A; Dupont, L; Fardon, TC; De Soyza, A; Hill, AT
• Is Part Of: Thorax. Volume 68(2013)Supplement 3
• Page Start: A64
• Page End: A65
• Publication Date: 2013-11-14
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2013-204457.131
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction: There are no risk stratification tools for morbidity and mortality in bronchiectasis. As more treatments become available, it is important to identify patients at risk of exacerbations, hospital admissions and mortality to target novel therapies. Methods: A prospective observational study at a specialist bronchiectasis clinic in Edinburgh, UK was used to derive a bronchiectasis severity index using cox-proportional hazards regression to identify independent predictors of mortality and hospital admission over 4 years follow-up. Averaged ß-coefficients were used to award points for each independent variable and the discrimination of a derived score was tested using the area under the receiver operator characteristic curve (AUC). The score was validated in independent cohorts from Dundee, UK (N = 218), Leuven, Belgium (N = 253), Monza, Italy (N = 105) and Newcastle, UK (N = 126). Results: 608 patients were included in the derivation cohort. Independent predictors of future hospital admissions were prior hospital admissions hazard ratio (HR) 13.5 (9.40–19.46), MRC dyspnoea score > 4, HR 2.42 (1.66–3.52), FEV1 <30% predicted HR 1.52 (1.03–2.25), Pseudomonas aeruginosa colonisation HR 2.16 (1.36–3.43), colonisation with other organisms HR 1.66 (1.12–2.44) and > 3 lobes involved on HRCT HR 1.48 (1.02–2.15). In the model for mortality, independent predictors were Age >70 years 8.57 (1.15–63.63), FEV1 <30% predicted HR 4.47 (1.60–12.53), prior hospital admissions HR 2.43 (1.30–4.53) and 3 or more exacerbations per year prior to the study HR 2.03 (1.02–4.03). The bronchiectasis severity index derived from these models was composed of prior hospitalisation (5 points), MRC dyspnoea score (0–3 points), FEV1 (0–3 points), bacterial colonisation (0- 3 points) Age (0–6 points) BMI <18.5 (2 points) Exacerbation frequency (0–2 points) and radiological extent (1 point). The AUC for mortality was 0.80 (0.74–0.86) and the AUC for hospitalisation was 0.88 (0.84–0.91). There was a clear difference in exacerbation frequency and quality of life using the St. Georges Respiratory Questionnaire between patients classified as low, intermediate and high risk by the score (p < 0.0001 for all comparisons). In the validation cohorts, the AUC for mortality ranged from 0.81–0.84 and for hospitalisation was AUC 0.80–0.88. Conclusions: The bronchiectasis severity index identifies patients at risk of future mortality, hospital admissions and exacerbations.